Department of Biochemistry, Microbiology, and Immunology, Molecular Genetics and Cardiac Regeneration Laboratory, University of Ottawa, Ontario, Canada (L.G., H.K., R.H., M.T., M.N.).
Department of Molecular Medicine, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University, Canada (Y.B., P.M.).
Circulation. 2018 Sep 4;138(10):1025-1038. doi: 10.1161/CIRCULATIONAHA.117.029506.
Bicuspid aortic valve (BAV), the most common congenital heart defect affecting 1% to 2% of the population, is a major risk factor for premature aortic valve disease and accounts for the majority of valve replacement. The genetic basis and mechanisms of BAV etiology and pathogenesis remain largely undefined.
Cardiac structure and function was assessed in mice lacking a Gata6 allele. Human GATA6 gene variants were analyzed in 452 BAV cases from the BAV consortium and 1849 controls from the Framingham GWAS (Genome Wide Association Study). GATA6 expression was determined in mice and human tissues using quantitative real-time polymerase chain reaction and immunohistochemistry. Mechanistic studies were carried out in cultured cells.
Gata6 heterozygous mice have highly penetrant right-left (RL)-type BAV, the most frequent type in humans. GATA6 transcript levels are lower in human BAV compared with normal tricuspid valves. Mechanistically, Gata6 haploinsufficiency disrupts valve remodeling and extracellular matrix composition through dysregulation of important signaling molecules, including matrix metalloproteinase 9. Cell-specific inactivation of Gata6 reveals an essential role for GATA6 in secondary heart field myocytes because loss of 1 Gata6 allele from Isl- 1-positive cells-but not from endothelial or neural crest cells-recapitulates the phenotype of Gata6 heterozygous mice.
The data identify a new cellular and molecular mechanism underlying BAV. The availability of an animal model for the most frequent human BAV opens the way for the elucidation of BAV pathogenesis and the development of much needed therapies.
二叶式主动脉瓣(BAV)是最常见的先天性心脏病,影响 1%至 2%的人群,是主动脉瓣疾病早发的主要危险因素,也是大多数瓣膜置换的原因。BAV 的遗传基础和发病机制仍很大程度上不明确。
在缺乏 Gata6 等位基因的小鼠中评估心脏结构和功能。在 BAV 联盟的 452 例 BAV 病例和弗雷明汉 GWAS(全基因组关联研究)的 1849 例对照中分析了人类 GATA6 基因变异。使用定量实时聚合酶链反应和免疫组织化学在小鼠和人组织中测定 GATA6 表达。在培养的细胞中进行了机制研究。
Gata6 杂合子小鼠具有高度易患的左右(RL)型 BAV,这是人类最常见的类型。与正常三尖瓣相比,人类 BAV 的 GATA6 转录水平较低。从机制上讲,Gata6 单倍不足通过失调重要信号分子,包括基质金属蛋白酶 9,破坏瓣膜重塑和细胞外基质组成。细胞特异性 Gata6 失活揭示了 GATA6 在次级心脏场心肌细胞中的重要作用,因为从 Isl-1 阳性细胞但不是内皮细胞或神经嵴细胞中丢失 1 个 Gata6 等位基因可重现 Gata6 杂合子小鼠的表型。
这些数据确定了 BAV 潜在的新的细胞和分子机制。具有最常见人类 BAV 动物模型的可用性为阐明 BAV 发病机制和开发急需的治疗方法开辟了道路。